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Abstract: As a group of biologically active compounds, polyether antibiotics (ionophores) show 
a broad spectrum of interesting pharmacological properties, ranging from anti-bacterial to anti-
cancer activities. There is increasing evidence that ionophores, including salinomycin (SAL), 
and their semi-synthetic analogues are promising candidates for the development of drugs 
against parasitic diseases. Our previous studies have shown that esterification and amidation of 
the C1 carboxylate moiety of SAL provides compounds with potent activity against 
Trypanosoma brucei, protozoan parasites responsible for African trypanosomiasis. In this paper, 
we present the synthetic pathways, crystal structures and anti-trypanosomal activity of C1 esters, 
amides and hydroxamic acid conjugates of SAL, its C20-oxo and propargylamine analogues as 
well novel C1/C20 doubly modified derivatives. Evaluation of the trypanocidal and cytotoxic 
activity using bloodstream forms of Trypanosoma brucei and human myeloid HL-60 cells 
revealed that the single-modified C20-oxo and propargylamine precursor molecules 10 and 16 
were the most anti-trypanosomal and selective compounds with 50% growth inhibition (GI50) 
values of 0.037 and 0.0035 µM, and selectivity indices of 252 and 300, respectively. Also the 
salicylhydroxamic acid conjugate of SAL (compound 9) as well as benzhydroxamic acid and 
salicylhydroxamic acid conjugates of 10 (compounds 11 and 12) showed promising trypanocidal 
activities with GI50 values between 0.032 to 0.035 µM but less favorable selectivities. The 
findings confirm that modification of SAL can result in derivatives with improved trypanocidal 
activity that might be interesting lead compounds for further anti-trypanosomal drug 
development.
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1. Introduction  
Polyether ionophores have been used in veterinary medicine for decades as non-hormonal 
growth promoters and as agents to control coccidiosis [1‒2]. In addition to the industrial use of 
ionophores in animal husbandry [3], some of them show anti-fungal, anti-viral, and anti-cancer 
activity [4‒6]. Salinomycin (SAL, 1, Scheme 1), a polyether K+-selective membrane ionophore 
from Streptomyces albus, seems to be the most promising agent in this context as several studies 
have shown activity against different human cancer cells, multi-drug resistant cancer cells, 
cancer stem cells and human tumour xenograft models in mice [5]. Although accidental 
poisonings have been reported, SAL was found to improve the condition in a small group of 
cancer patients without any long-term acute adverse effects when used in the appropriate dose 
[5,7-8]. Mechanistically, the effects on several signal transduction pathways were suggested to 
explain the change in phenotype composition after SAL treatment, including Wnt signaling 
pathway involved in tumorigenesis and embryogenesis. Other pathways that were inhibited by 
SAL include KRas and modulation of Hedgehog signaling [5]. 
It should be pointed out that compounds that display anti-cancer activity, very often are 
also active against African trypanosomes [9]. These protozoan parasites cause sleeping sickness 
in humans and nagana disease in cattle [10–12], and are transmitted by the bites of infected tsetse 
flies (Glossina sp.) that are only found in rural regions of sub-Saharan Africa [13–14]. 
Historically, African trypanosomiasis has been a serious economic and public health problem in 
Africa, causing several epidemics over the last century [15]. According to the World Health 
Organization, the estimated number of actual cases is below 20,000, but the estimated population 
at risk is still 65 million people [16]. Because of nagana disease, livestock farming is difficult in 
many regions of sub-Saharan Africa and this is exacerbated by the rise of drug resistant 
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trypanosomes [10]. As the few drugs that are used for treatment of both sleeping sickness and 
nagana disease are outdated, have limited efficacy and may produce adverse side reactions 
[17‒19], novel and better-tolerated therapeutic strategies are a critical need. 
Recently, we have demonstrated that SAL and semi-synthetic SAL derivatives obtained 
by chemical modification of the C1 carboxylate moiety inhibit the growth of culture-adapted 
bloodstream forms of Trypanosoma brucei in vitro at sub-micromolar concentration [20]. 
Interestingly, certain SAL analogues have been found to display enhanced trypanocidal activity 
compared to that of the parent ionophore with GI50 values in the mid nanomolar range and MIC 
values below 1.0 μM. These anti-trypanosomal activities are within the range of the drugs used 
to treat African trypanosomiasis [20]. 
Besides C1 carboxylate moiety [20‒23], the allylic C20 hydroxyl group of SAL has also 
been found to be an interesting site for chemical modification, as C20-O-acyl and C20-amine 
derivatives have been shown to have an improved biological activity profile compared to that of 
unmodified compound [24‒25]. Recently, we have reported that doubly C1/C20 modified 
analogues of SAL display anti-cancer activity in the low µM range with low toxicity towards 
normal cells. In addition, these derivatives also showed good activity against a multi-drug 
resistant cancer cell line [26]. These findings indicate that multiple modifications of the SAL 
molecule may be also a promising synthetic strategy to improve the biological activity of this 
ionophore against T. brucei. 
On the basis of our recent findings, we designed a completely novel class of multiply 
modified SAL derivatives by merging desirable structural features to generate promising anti-
trypanosomal agents. In this context, methods for efficient synthetic access to novel double-
modified analogues of C20-oxo and C20-propargylamine derivatives of a series of selected C1 
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esters, amides and hybrids with hydroxamic acids are presented (Schemes 1‒3). The newly 
synthesized compounds were evaluated in vitro for their trypanocidal and cytotoxic activity 
using bloodstream form of T. brucei and human myeloid HL-60 cells, respectively. The 
trypanocidal mechanism of the most active derivatives was investigated by swelling experiments. 
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Scheme 1. Synthesis of C1 esters and amides of C20-oxo-salinomycin. 
 
 
Scheme 2. Synthesis of C1 conjugates of C20-oxo-salinomycin with hydroxamic acids. 
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Scheme 3. Synthesis of double-modified analogues 14 and 15. 
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2. Results and discussion 
2.1. Analogue design and synthesis 
Firstly, to expand the library of novel doubly C1/C20 modified compounds, SAL 
analogues were designed on the basis of the most active C1 esters, amides and conjugates with 
hydroxamic acids obtained in previous studies [21‒23], i.e. ester 2 and amide 4 (Scheme 1) as 
well as hybrids 8 and 9 (Scheme 2). Secondly, propargyl ester 3 (Scheme 1) and propargyl 
amide 13 (Scheme 3) were also included in our studies because of their structural similarity that 
might be of help in determination of structure-activity relationship (SAR). In addition, both 
structures were previously shown to display promising biological activity [23]. Thirdly, with 
respect to the modification of the C20 position, chemoselective oxidation of C20 hydroxyl was 
performed for all mentioned compounds to give access to six novel C20-oxo analogues 
(Schemes 1‒3). Further stereoselective reductive amination of enone 14 (Scheme 3) was 
executed as well, as such a modification was expected to improve the biological activity of the 
resulting double-modified analogue (Scheme 3, compound 15) [24]. Finally, to compare the 
trypanocidal activity of corresponding derivatives as well as to facilitate SAR analysis, both SAL 
precursors, C20 ketone 10 and C20 amine 16, were also synthesized (Scheme 2 and 3) [24]. 
 The allylic C20 hydroxyl group of the series of C1 esters and amides was 
chemoselectively oxidized to the corresponding C20 ketones with moderate to good yields (72–
90%) using activated manganese(IV) oxide (Scheme 1, compounds 5‒7 and Scheme 3, 
compound 14) [24]. In all cases, full selectivity towards the C20 hydroxyl was observed. The 
synthesis of the double-modified analogues 11 and 12 (Scheme 2) was, however, slightly more 
challenging as the C20 hydroxyl group of the SAL hybrids with hydroxamic acids did not 
undergo oxidation under the reaction conditions. In order to obtain these compounds, it was 
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therefore necessary to synthesize C20-oxo-salinomycin 10 prior to its conjugation with 
benzhydroxamic acid or salicylhydroxamic acid (Scheme 2).  
 In 2017, Rodriguez and co-workers synthesized a series of C20-amine derivatives of 
SAL and found that the C20-propargylamine analogue (Scheme 3, compound 16) was the most 
interesting one. The compound showed almost 10-times higher anti-proliferative activity against 
breast cancer stem cells than SAL, both in vitro and in vivo, with IC50 value of ~100 nM whilst 
maintaining selectivity over control cells [24]. This finding inspired us to obtain a novel doubly 
modified analogue of SAL by transforming compound 14 to its corresponding C20-
propargylamine 15 (Scheme 3, Method A), according to the protocol mentioned above [24]. In 
the first step of reductive amination, enone 14 reacted with propargylamine in the presence of 
acetic acid to form the imine in situ. Using the Luche reduction, the intermediate imine was then 
reduced by the slow addition of NaBH3CN in the presence of CeCl3, which resulted in the 
stereoselective formation of the novel double-modified derivative 15 with 64% yield (Scheme 3, 
Method A). Compound 15 was also obtained using the ‘reversed’ reaction sequence. Ketone 10 
was converted into amine 16 [24], followed by an amidation reaction of C1 carboxyl moiety that 
resulted in the formation of 15 with 38% yield (Scheme 3, Method B). The overall yield of this 
transformation was however lower than the first one. 
 The purity and structure of the newly synthesized compounds were determined using 
scXRD, spectroscopic (FT-IR, NMR) and spectrometric (ESI MS) methods. The 1H and 13C 
NMR spectra of selected SAL precursors and all novel double-modified analogues are included 
in Supplementary Information. The 19F NMR spectra of 5 and 7 that contain additional 
fluorine atoms in their structures are also included (see Supplementary Information). Briefly, 
in the 13C NMR spectra (in CD2Cl2 or in CDCl3) of double-modified derivatives, the most 
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characteristic signal of α,β-unsaturated ketone at the C20 position was observed in a narrow 
range of 189.3–190.5 ppm. In the 1H NMR spectrum of 15, the characteristic signal of the 
alkynyl hydrogen of the C20 terminal alkyne moiety was observed at 2.21 (t, J = 2.4 Hz, 1H) 
ppm. 
 
2.2. X-ray analysis 
Structural data of SAL derivatives are very important to understand their biological 
properties, to determine SAR as well as related investigation. We have therefore characterized 
compounds 14 and 15 using the single-crystal X-ray diffraction (scXRD) method, and compared 
the obtained structures to the structure of the propargyl amide 13 described previously [27].  
Single crystals of 14 (mp 115–119 °C) and 15 (mp 169–173 °C) were grown by 
crystallisation in acetonitrile solution. Compound 14 crystallized in the non-centrosymmetric 
space group P21 of the monoclinic system with one molecule in the asymmetric unit, while 
compound 15 crystallized in the non-centrosymmetric space group of the triclinic system with 
two molecules in the asymmetric unit. Crystal data and details of the refinement parameters are 
presented in Table S1 (Supplementary Information). The asymmetric unit of the SAL 
derivatives 14 and 15 is illustrated in Figure 1 and Figure 2, respectively.  
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Figure 1. View of the asymmetric unit of 14. 
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Figure 2. View of the asymmetric unit of 15 (Mol. 1 on the left, and Mol. 1B on the right).  
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In the crystals, the molecules of both SAL derivatives exhibit pseudo-cyclic 
conformation. This conformation is stabilized by the O―H···O hydrogen bond formed by the 
hydroxyl group linked to C9 carbon atom and the O5 oxygen atom of the five-membered ring of 
the spiroketal system (Supplementary Information, Table S2) and, in addition, by an 
N―H···O hydrogen bond formed by the N―H of the amide group as a donor and the hydroxyl 
group as an acceptor that adds partly into the stabilization energy of the pseudo-cyclic 
conformation (Figure 2). Both independent molecules in the crystal of 15 (Mol. 1 and Mol. 1B) 
exhibit similar conformation (Supplementary Information, Figure S1), but differ from that of 
14 due to the substitution effect at the C20 atom (Supplementary Information, Figure S2). The 
spiroketal system consists of two six-membered and one five-membered rings, in which the 
central rings are unsaturated. The arrangement of the atoms around the C17 and C21 heads is 
tetrahedral, so that the junctions between the five- and six-membered rings and between both six-
membered rings are of the spiro type. The unsaturated six-membered ring with one double bond 
character (C18=C19), with a distance of 1.326(5) Å in 14 and 1.304(10) and 1.313(9) Å in the 
independent Mol. 1 and Mol. 1B molecules in 15, has envelope conformation where C21 is out 
of the plane formed by the other ring atoms by 0.388(5) Å in 14, and 0.508(8) and 0.486(8) Å in 
Mol. 1 and Mol. 1B in 15, respectively. The five-membered ring of the spiro system exhibits 
twisted conformation with the C21 atom out of the mean plane defined by the other atoms of the 
ring by 0.443(5) Å in 14, and 0.414(8) and 0.411(8) Å in Mol. 1 and Mol. 1B in 15, respectively. 
All saturated six-membered rings exhibit chair conformation in both 14 and 15 structures. The 
X-ray crystallographic analysis confirmed the structural assignment (Scheme 3). The pseudo-
cyclic conformation of 14 is quite similar to the conformation of SAL propargyl amide 13 
(Supplementary Information, Figure S3), but the pseudo-cyclic conformation of 15 due to the 
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substitution effect at C20 is different to that of SAL propargyl amide 13 (Supplementary 
Information, Figure S4) [27]. 
 
2.3. Anti-trypanosomal activity 
All SAL precursors and their newly synthesized double-modified derivatives were 
evaluated for their in vitro activity against bloodstream forms of T. brucei and human myeloid 
HL-60 cell using the resazurin cell viability assay [28,29]. All compounds showed a dose-
dependent inhibitory effect on the growth of bloodstream-form trypanosomes (Table 1). Of the 
single-modified C1 esters and amides, only the benzhydroxamic acid conjugate 9 displayed a 6-
fold enhanced trypanocidal activity compared to that of SAL with a 50% growth inhibition 
(GI50) value of 0.035 µM. Both single-modified C20 analogues, C20-oxo and C20-
propargylamine derivatives 10 and 16, also exhibited increased anti-trypanosomal activity with 
similar GI50 values. Of the double-modified compounds, the benzhydroxamic acid and 
salicylhydroxamic acid conjugates 11 and 12 showed improved trypanocidal activity with GI50 
values of 0.032 and 0.034 µM. However, their anti-trypanosomal activity was not better than that 
of their parent compound 10. 
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Table 1.  GI50 values and ratios of SAL derivatives for T. brucei and HL-60 cells. 
 
Single-modified salinomycin derivatives 
 
 Double-modified salinomycin derivatives 
 
No. R1 
T. brucei HL-60 Selectivity  
No. 
T. brucei HL-60 Selectivity 
GI50 (μM)a GI50 (μM)a GI50 ratiob  GI50 (μM)a GI50 (μM)a GI50 ratiob 
1  0.21 ± 0.06 6.63 ± 3.23 31.6  10 0.037 ± 0.005 9.21 ± 4.25 252 
2  2.90 ± 0.19 32.5 ± 0.8 11.2 
 5 3.01 ± 0.34 >100 >33.2 
3 
 
2.93 ± 0.14 30.0 ± 1.9 10.2  6 3.03 ± 0.06 29.6 ± 2.0 9.8 
4 
 
2.87 ± 0.05 11.6 ± 1.6 4.0 
 
7 2.99 ± 0.11 94.7 ± 7.7 31.7 
8 
 
0.17 ± 0.08 3.58 ± 0.98 21.1 
 
11 0.032 ± 0.001 2.24 ± 0.87 70.0 
 16 
9 
 
0.035 ± 0.002 2.12 ± 0.31 60.6 
 
12 0.034 ± 0.001 1.93 ± 0.77 56.8 
13 
 
3.06 ± 0.16 35.5 ± 0.1 11.6 
 
14 3.18 ± 0.08 38.6 ± 7.6 12.1 
  
 
 
 
 
16  0.035 ± 0.005 10.5 ± 6.5 300  15 3.04 ± 0.13 38.9 ± 2.5 12.8 
Suraminc 0.032 ± 0.003 >100 >3125      
a Data shown are mean values ± SD of three independent experiments; b GI50 ratio = GI50(HL-60)/GI50(T. brucei); 
c Reference control. 
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Most derivatives showed lower cytotoxic activity against HL-60 cells than SAL (Table 
1). However, compounds 9, 11 and 12 displayed increased cytotoxicities. As the single modified 
C20 derivatives were less cytotoxic towards HL-60 cells, their selectivity index (GI50 ratio of 
cytotoxic to trypanocidal activity) was 8–9 fold increased relative to that of SAL (Table 1). 
Noteworthy is the finding that all five compounds (9–12 and 16) with increased 
trypanocidal activity displayed GI50 values similar to the GI50 value of suramin, one of the drugs 
used in the treatment of sleeping sickness (Table 1). However, as suramin is nontoxic to HL-60 
cells, the selectivity indices of the derivatives were less favorable than the GI50 ratio of suramin, 
It has been shown that SAL derivatives with enhanced trypanocidal activity display 
increased ionophoretic activity when compared to that of the unmodified parent compound [20]. 
Therefore, we wanted to check whether the enhanced anti-trypanosomal activity of compounds 
9–12 and 16 was also due to increased ionophoresis. Changes in cell volume were determined by 
swelling experiments using the light scattering method previously described [20]. Only the C20-
oxo derivative 10 produced an increased swelling in bloodstream-form trypanosomes while the 
C20-propargylamine derivative 16 generated a similar swelling in the parasites as the parent 
compound (Figure 3). The other three compounds displayed lower (9) and much lower (11 and 
12) ionophoresis (Figure 3). Based on their low GI50 values (0.032–0.035 μM, Table 1) in 
connection with their low ionophoretic activity, the trypanocidal activity of compounds 9, 11 and 
12 may be not only due to their ionophoretic properties but probably to other mechanisms of 
toxic action. 
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Figure 3. Effect of SAL derivatives on the cell volume of bloodstream forms of T. brucei. Trypanosomes (5   107  
cells ml‒1) were incubated with 100 µM ionophore in Baltz medium in the presence of 0.9% DMSO. Every  10 min , 
the absorbance at 490 nm was measured. Black circles, DMSO control; grey squares, SAL control; red, single-
modified derivatives (squares, 9; circles, 10; triangles, 16); blue, double-modified derivatives (squares, 11; triangles, 
12). Note that a decrease in absorbance corresponds to an increase in cell volume. For clarity, only mean values o f 
three experiments are shown. The standard deviations ranged from 0.1 to 12.1 percentage points. 
 
Evaluation of the trypanocidal activity of the new SAL derivatives has shown that 
modification of the C20 hydroxyl group to its ketone and propargylamine analogues 10 and 16 
gave compounds with increased anti-trypanosomal activity. Further modification of 10 or 16 at 
their C1 position did not lead to an additional increase in trypanocidal activity. The anti-
trypanosomal activity of the double-modified compounds was either decreased (5–7, 14 and 15) 
or stayed the same (11 and 12). As the cytotoxic activity of the double-modified derivatives 
paralleled their trypanocidal activity, their selectivity was not much different from that of SAL. 
 
3. Conclusions 
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In summary, a series of novel double-modified SAL analogues derivatized at their 
C1/C20 positions was devised. All newly designed compounds were synthesized in moderate 
to good yields. Of advantage were the straightforward protocols that allowed simple reaction 
workup and convenient isolation of the analogues.  
X-ray single crystal analyses of both SAL derivatives 14 and 15 showed pseudo-cyclic 
conformation of the skeletal molecules that were stabilized by the intramolecular O―H···O and 
N―H···O hydrogen bonds. A slight differences in the conformation between these SAL 
derivatives resulted from the substitution effect at the carbon atom C20 in the unsaturated six-
membered ring. 
With respect to trypanocidal activity, double-modified derivatives showed at best anti-
trypanosomal activity similar to that of their single-modified starting molecules, wherein 
compounds 11 and 12 seem to be the most promising ones in this group. However, their 
selectivity was not significantly improved. The most trypanocidal and selective compounds were 
the SAL derivatives 10 and 16 that were single-modified at their C20 position. These two 
analogues match the activity criteria for drug candidates for African trypanosomiasis (GI50 <1 
μM; selectivity >100). 
 
4. Experimental 
4.1. General procedures 
All precursors (except for hydroxamic acids, see section 4.2 for details) and all solvents 
were obtained from Merck or Trimen Chemicals S.A. (Poland), and were used as received 
without further purification. CD2Cl2 and CDCl3 spectral grade solvents were stored over 3Å 
molecular sieves for several days. All manipulations were carried out under nitrogen atmosphere 
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in oven-dried glassware. Reaction mixtures were stirred using teflon-coated magnetic stir bars. 
Reaction mixtures were monitored by thin layer chromatography (TLC) using aluminum-backed 
plates (Merck 60F254). TLC plates were visualized by UV-light (254 nm), followed by 
treatment with phosphomolybdic acid (PMA, 5% in absolute EtOH) and gentle heating. Products 
of the reactions were purified using CombiFlash® Rf+ Lumen Flash Chromatography System 
(Teledyne Isco) with integrated ELS and UV detectors. All solvents used in flash 
chromatography were of HPLC grade (Merck) and were used as received. Solvents were 
removed using a rotary evaporator. 
NMR spectra were recorded on a Varian 400 (1H NMR at 403 MHz, 13C NMR at 101 
MHz, and 19F NMR at 379 or 282 MHz) magnetic resonance spectrometer. 1H NMR spectra are 
reported in chemical shifts downfield from TMS using the respective residual solvent peak as 
internal standard (CD2Cl2 δ 5.32 ppm and CDCl3 δ 7.26 ppm). 1H NMR spectra are reported as 
follows: chemical shift (δ, ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
hept = heptet, dd = doublet of doublets, dt = doublet of triplets, dq = doublet of quartets, ddd = 
doublet of doublet of doublets, ddt = doublet of doublet of triplets, dtd = doublet of triplet of 
doublets, td = triplet of doublets, tdd = triplet of doublet of doublets, qd = quartet of dublets, m = 
multiplet), coupling constant(s) in Hz, and integration. Significant peaks are reported within the 
overlapping ~2.00–0.50 ppm region of the 1H NMR spectra. 13C NMR spectra are reported in 
chemical shifts downfield from TMS using the respective residual solvent peak as internal 
standard (CD2Cl2 δ 53.84 ppm and CDCl3 δ 77.16 ppm). 19F NMR spectra are reported in 
chemical shifts upfield from TMS using CFCl3 as internal standard. Line broadening parameters 
were 0.5 or 1.0 Hz, while the error of chemical shift value was 0.1 ppm. 
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Infrared spectra in the mid infrared region were recorded in KBr tablets on an IFS 113v 
FT-IR spectrophotometer (Bruker) equipped with a DTGS detector, and are reported as follows: 
wavenumbers (cm-1), description (w = weak, m = medium, s = strong, br = broad). The spectra 
were taken on resolution 2 cm–1, NSS = 64. The Happ-Genzel apodization function was used. 
Electrospray ionization (ESI) mass spectra were recorded on a Waters/Micromass ZQ 
mass spectrometer (Waters Alliance) equipped with a Harvard syringe pump. Samples were 
prepared in dry acetonitrile, and were infused into the ESI source using a Harvard pump at a flow 
rate of 20 ml min–1. The ESI source potentials were: capillary 3 kV, lens 0.5 kV, and extractor 4 
V. Standard ESI mass spectra were recorded at the cone voltages of 10 and 30 V. The source 
temperature was 120 °C and the desolvation temperature was 300 °C. Nitrogen was used as the 
nebulizing and desolvation gas at flow-rates of 100 dm3 h–1. Mass spectra were acquired in the 
positive ion detection mode with unit mass resolution at a step of 1 m/z unit. The mass range for 
ESI experiments was from m/z = 300 to m/z = 1100. 
  
4.2. Synthesis 
Salinomycin sodium salt was isolated from commercially available veterinary premix 
SACOX® following acidic extraction, using the procedure described by us previously [22‒23]. 
Briefly, isolated sodium salt of salinomycin was dissolved in CH2Cl2 and stirred vigorously with 
a layer of aqueous sulphuric acid (pH = 1.0). The organic layer containing SAL was washed with 
distilled water, and then CH2Cl2 was evaporated under reduced pressure to dryness giving SAL 
as a clear oil. After 3-times repeated evaporation with n-pentane this oil was transformed to 
white amorphous solid. The spectroscopic data of SAL were in agreement with previously 
published data [30]. 
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Hydroxamic acid precursors were obtained from the corresponding carboxylic acids 
according to the procedure published by Jirgensons et al. [31], and used then for the synthesis of 
SAL conjugates following the procedure described by Wu et al. [21]. All SAL C1 esters and 
amides were prepared using the procedures described by us previously [22‒23]. Compounds 10 
and 16 were prepared following the procedures described by Rodriguez et al. [24]. The NMR 
data of all the compounds were in good agreement with those found in the reference literature. 
 
4.2.1. General procedure for preparation of novel C20-oxo derivatives of salinomycin esters and 
amides (analogues 5‒7 and 14) 
To a stirred solution of SAL ester or amide (1.0 equiv.) in CH2Cl2 at room temperature, 
activated manganese(IV) oxide (20.0 equiv.) was added in one portion. The resulting black 
suspension was stirred vigorously for 3 days, and then filtrated over celite. The filtrate was 
diluted with CH2Cl2 and washed with an aqueous solution of H2SO4 (pH = 1.0) and distilled 
water. The organic layer was separated and concentrated under reduced pressure to give a 
colorless oil. Purification on silica gel using the CombiFlash system (EtOAc/n-hexane) gave the 
pure products of the reactions for 5‒7 and 14 (72–90% yield) as colorless oils. After 3-times 
repeated evaporation with n-pentane the oils were transformed to white amorphous solids. 
 
4.2.1.1. 2,2,2-trifluoroethyl ester of C20-oxo-salinomycin 5 
Yield: 760 mg, 88%. Isolated as a white amorphous solid, >95% pure by NMR and a 
single spot by TLC; Rf: 0.59 in 33% EtOAc/n-hexane. UV-active and strains green with PMA; 
1H NMR (403 MHz, CDCl3) δ 7.24 (d, J = 10.8 Hz, 1H), 6.23 (d, J = 10.8 Hz, 1H), 4.75 (ddd, J 
= 17.3, 12.9, 8.6 Hz, 1H), 4.65 (ddd, J = 17.3, 13.0, 8.7 Hz, 1H), 4.06 (dd, J = 10.9, 5.5 Hz, 1H), 
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3.88 (ddd, J = 10.1, 5.3, 1.0 Hz, 1H), 3.76 (q, J = 6.9 Hz, 1H), 3.64 (dd, J = 10.1, 3.9 Hz, 1H), 
3.57 (dd, J = 9.8, 1.9 Hz, 1H), 3.48 (s, 1H), 3.42–3.34 (m, 1H), 3.10 (td, J = 10.9, 4.4 Hz, 1H), 
2.97 (dq, J = 10.1, 7.1 Hz, 1H), 2.78–2.55 (m, 4H), 2.19–2.03 (m, 2H), 2.02–0.66 (m, 50H) ppm; 
13C NMR (101 MHz, CDCl3) δ 214.4, 190.4, 173.9, 143.6, 127.3, 124.6, 121.8, 105.4, 97.5, 88.6, 
78.5, 77.1, 74.5, 72.0, 71.9, 71.0, 70.0, 60.8, 60.4, 57.0, 48.8, 47.2, 39.7, 39.0, 36.3, 34.2, 34.1, 
34.0, 30.4, 29.1, 28.0, 26.2, 22.7, 22.5, 20.7, 19.7, 18.9, 17.5, 15.8, 14.3, 13.9, 12.0, 11.5, 11.0, 
7.2, 6.4 ppm; 19F NMR (282 MHz, chloroform-d) δ –73.97 ppm; FT-IR (KBr tablet): 3581 (br, 
m), 3458 (br, m), 2967 (s), 2939 (s), 2882 (s), 1755 (s), 1736 (m), 1697 (s), 1461 (s), 1446 (s), 
1442 (s), 1406 cm–1; ESI MS (m/z): [M+Na]+ Calcd for C44H69F3NaO11 853; Found 853. 
 
4.2.1.2. Propargyl ester of C20-oxo-salinomycin 6 
Yield: 380 mg, 79%. Isolated as a white amorphous solid, >95% pure by NMR and a 
single spot by TLC; Rf: 0.64 in 33% EtOAc/n-hexane. UV-active and strains green with PMA; 
1H NMR (403 MHz, CD2Cl2) δ 7.23 (d, J = 10.8 Hz, 1H), 6.19 (d, J = 10.8 Hz, 1H), 4.82 (qd, J = 
15.8, 2.5 Hz, 2H), 3.97 (dd, J = 11.0, 5.5 Hz, 1H), 3.84 (ddd, J = 10.1, 5.0, 1.0 Hz, 1H), 3.72 (q, 
J = 6.8 Hz, 1H), 3.65 (dd, J = 10.1, 3.4 Hz, 1H), 3.54 (dd, J = 9.8, 1.9 Hz, 1H), 3.41–3.32 (m, 
1H), 3.02 (td, J = 10.7, 4.7 Hz, 1H), 2.93 (dq, J = 10.1, 7.1 Hz, 1H), 2.68–2.63 (m, 2H), 2.63–
2.51 (m, 2H), 2.13–1.98 (m, 2H), 1.96–0.61 (m, 52H) ppm; 13C NMR (101 MHz, CD2Cl2) δ 
214.5, 190.5, 175.2, 143.9, 127.6, 105.8, 97.9, 89.1, 79.0, 78.6, 77.5, 75.1, 72.6, 72.2, 71.1, 70.4, 
57.0, 52.7, 49.0, 47.5, 40.2, 39.2, 36.7, 34.6, 34.4, 34.2, 30.8, 29.6, 28.5, 26.6, 23.3, 23.1, 21.1, 
20.1, 18.7, 17.7, 15.9, 14.5, 14.2, 12.6, 11.8, 11.2, 7.5, 6.6 ppm, one signal overlapped; FT-IR 
(KBr tablet): 3541 (br, m), 3469 (br, m), 3313 (m), 2966 (s), 2938 (s), 2877 (s), 2124 (w), 1745 
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(s), 1724 (s), 1700 (s), 1460 (s), 1444 (s), 1405 (s) cm–1; ESI MS (m/z): [M+Na]+ Calcd for 
C45H70NaO11 810; Found 810. 
 
4.2.1.3. 4-fluorophenethyl amide of C20-oxo-salinomycin 7 
Yield: 320 mg, 90%. Isolated as a white amorphous solid, >95% pure by NMR and a 
single spot by TLC; Rf: 0.46 in 50% EtOAc/n-hexane. UV-active and strains green with PMA; 
1H NMR (403 MHz, CDCl3) δ 7.29–7.22 (m, 3H), 7.00–6.91 (m, 2H), 6.32 (t, J = 5.8 Hz, 1H), 
6.23 (d, J = 10.7 Hz, 1H), 4.03 (dd, J = 9.7, 3.2 Hz, 1H), 3.85 (dd, J = 10.8, 4.2 Hz, 1H), 3.78–
3.60 (m, 4H), 3.59–3.50 (m, 1H), 3.51–3.47 (m, 1H), 3.35 (dd, J = 11.0, 2.1 Hz, 1H), 3.14 (s, 
1H), 2.93–2.80 (m, 3H), 2.73 (td, J = 10.7, 4.4 Hz, 1H), 2.70–2.65 (m, 1H), 2.60 (ddd, J = 11.7, 
7.2, 4.0 Hz, 1H), 2.14–0.56 (m, 53H) ppm; 13C NMR (101 MHz, CDCl3) δ 214.1, 190.1, 175.1, 
162.7, 160.3, 143.4, 135.20, 135.17, 130.34, 130.26, 127.6, 115.1, 114.9, 105.7, 97.4, 89.0, 78.5, 
77.4, 75.3, 72.5, 71.4, 70.8, 70.2, 55.3, 49.0, 46.3, 40.5, 39.7, 38.7, 36.4, 35.0, 34.4, 34.1, 33.6, 
30.4, 29.1, 28.3, 26.5, 23.5, 22.6, 20.6, 17.6, 17.5, 15.8, 14.4, 12.6, 11.7, 11.5, 7.6, 6.5 ppm; FT-
IR (KBr tablet): 3505 (m), 3424 (br, m), 3359 (m), 3057 (w), 2965 (s), 2931 (s), 2876 (s), 1711 
(br, s), 1709 (br, s), 1659 (s), 1602 (m), 1524 (s), 1512 (s), 1466 (s), 1456 (s), 1440 (s), 1402 (s) 
cm–1; ESI MS (m/z): [M+Na]+ Calcd for C50H76FNNaO10 893; Found 893. 
 
4.2.1.4. Propargyl amide of C20-oxo-salinomycin 14 
Yield: 600 mg, 72%. Isolated as a white amorphous solid, >95% pure by NMR and a 
single spot by TLC; Rf: 0.60 in 50% EtOAc/n-hexane. UV-active and strains green with PMA; 
1H NMR (403 MHz, CD2Cl2) δ 7.29 (d, J = 10.8 Hz, 1H), 7.19–7.08 (m, 1H), 6.20 (d, J = 10.7 
Hz, 1H), 4.27 (ddd, J = 17.6, 6.3, 2.5 Hz, 1H), 4.03 (ddd, J = 17.7, 5.0, 2.5 Hz, 1H), 3.97–3.84 
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(m, 2H), 3.81 (q, J = 6.9 Hz, 1H), 3.76–3.65 (m, 2H), 3.62 (dd, J = 9.8, 2.0 Hz, 1H), 3.39–3.28 
(m, 1H), 3.20 (d, J = 3.8 Hz, 1H), 2.85–2.66 (m, 2H), 2.62 (dt, J = 8.8, 3.0 Hz, 1H), 2.58–2.47 
(m, 1H), 2.17 (t, J = 2.5 Hz, 1H), 2.07–0.53 (m, 53H) ppm; 13C NMR (101 MHz, CD2Cl2) δ 
214.1, 190.0, 175.1, 143.6, 128.4, 106.4, 97.8, 89.7, 81.8, 79.7, 78.2, 75.5, 73.3, 71.7, 71.2, 70.2, 
70.1, 54.3, 48.4, 46.3, 40.1, 38.6, 36.8, 35.0, 34.4, 33.2, 30.8, 29.4, 28.8, 26.9, 24.9, 23.0, 20.9, 
20.5, 17.3, 17.1, 15.9, 14.7, 14.6, 13.6, 11.8, 11.4, 8.0, 6.9 ppm, one signal overlapped; FT-IR 
(KBr tablet): 3472 (m), 3430 (br, m), 3338 (m), 3319 (m), 2966 (s), 2934 (s), 2878 (s), 2128 (w), 
1703 (br, s), 1653 (s), 1531 (s), 1460 (s), 1443 (m), 1437 (m) cm–1; ESI MS (m/z): [M+Na]+ 
Calcd for C45H71NNaO10 808; Found 808. 
 
4.2.2. General procedure for preparation of novel conjugates of C20 -oxo-salinomycin with 
hydroxamic acids (analogues 11 and 12) 
To a stirred solution of C20-oxo-salinomycin 10 (1.0 equiv.) in anhydrous CH2Cl2 at 
room temperature, 1,3-dicyclohexylcarbodiimide (2.0 equiv.) and an excess of 4-
dimethylaminopyridine were added, followed by addition of the corresponding hydroxamic acid 
(5.0 equiv.) in one portion. The resulting pale yellow solution was stirred for 24 hours, and then 
the organic solvents were evaporated under reduced pressure to dryness. The yellow residue was 
re-suspended in CH2Cl2 and filtered to remove the 1,3-dicyclohexylurea by-product. The filtrate 
was evaporated under reduced pressure and purified on silica gel using the CombiFlash system 
(EtOAc/n-hexane) to give the pure products of the reaction for 11 and 12 (26‒31% yield) as clear 
oils. After 3-times repeated evaporation with n-pentane the oils were transformed to white 
amorphous solids. 
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4.2.2.1. Benzhydroxamic acid conjugate of C20-oxo-salinomycin 11 
Yield: 323 mg, 31%. Isolated as a white amorphous solid, >95% pure by NMR and a 
single spot by TLC; Rf: 0.78 in 50% EtOAc/n-hexane. UV-active and strains green with PMA; 
1H NMR (401 MHz, CD2Cl2) δ 11.05 (s, 1H), 8.19–8.05 (m, 2H), 7.59–7.49 (m, 1H), 7.48–7.38 
(m, 2H), 7.23 (d, J = 10.8 Hz, 1H), 6.20 (d, J = 10.8 Hz, 1H), 4.05–3.91 (m, 2H), 3.84–3.74 (m, 
2H), 3.69 (dd, J = 9.7, 1.9 Hz, 1H), 3.30 (dd, J = 11.5, 2.3 Hz, 1H), 3.15 (ddd, J = 11.0, 8.7, 6.1 
Hz, 1H), 2.94–2.82 (m, 2H), 2.64–2.51 (m, 2H), 2.38 (d, J = 5.3 Hz, 1H), 2.04–1.96 (m, 1H), 
1.95–0.50 (m, 52H) ppm; 13C NMR (101 MHz, CD2Cl2) δ 216.6, 189.3, 173.9, 165.6, 142.5, 
132.4, 131.6, 128.7, 128.5, 128.3, 105.9, 97.9, 90.2, 80.4, 76.8, 75.0, 72.8, 72.7, 70.9, 69.5, 54.1, 
46.9, 46.7, 40.2, 38.3, 36.5, 34.6, 33.0, 32.7, 31.3, 29.9, 28.7, 26.8, 25.4, 23.5, 21.3, 20.3, 17.1, 
16.6, 15.9, 14.9, 14.5, 14.2, 11.9, 11.2, 7.8, 6.8 ppm; FT-IR (KBr tablet): 3570 (m), 3501 (br, m), 
3321 (br, m), 3064 (m), 2965 (s), 2938 (s), 2879 (s), 1781 (s), 1702 (br, s), 1637 (m), 1602 (m), 
1583 (m), 1542 (m), 1502 (m), 1462 (s), 1446 (s), cm-1; ESI MS (m/z): [M+Na]+ Calcd for 
C49H73NNaO12 891; Found 891. 
 
4.2.2.2. Salicylhydroxamic acid conjugate of C20-oxo-salinomycin 12 
Yield: 130 mg, 26%. Isolated as a white amorphous solid, >95% pure by NMR and a 
single spot by TLC; Rf: 0.35 in 50% EtOAc/n-hexane. UV-active and strains green with PMA; 
1H NMR (401 MHz, CD2Cl2) δ 11.71 (s, 1H), 11.25 (s, 1H), 8.25 (dd, J = 8.0, 1.4 Hz, 1H), 7.43 
(ddd, J = 8.6, 7.3, 1.5 Hz, 1H), 7.26 (d, J = 10.8 Hz, 1H), 6.95 (dd, J = 8.4, 1.0 Hz, 1H), 6.90–
6.83 (m, 1H), 6.22 (d, J = 10.8 Hz, 1H), 4.06–3.97 (m, 2H), 3.86 (dd, J = 10.1, 2.8 Hz, 1H), 3.77 
(q, J = 6.9 Hz, 1H), 3.71 (dd, J = 9.6, 1.9 Hz, 1H), 3.30 (dd, J = 11.6, 2.3 Hz, 1H), 3.18 (ddd, J = 
11.0, 7.7, 6.9 Hz, 1H), 2.90 (dq, J = 9.5, 7.4 Hz, 2H), 2.66 (dt, J = 9.1, 2.4 Hz, 1H), 2.64–2.51 
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(m, 1H), 2.40 (d, J = 5.7 Hz, 1H), 2.10–0.50 (m, 53H) ppm; 13C NMR (101 MHz, CD2Cl2) δ 
217.2, 189.4, 173.8, 169.0, 162.1, 142.7, 135.2, 128.8, 127.9, 119.2, 118.5, 112.4, 106.1, 98.1, 
90.6, 80.6, 77.0, 75.2, 73.2, 72.9, 71.1, 69.6, 54.2, 47.0, 46.7, 40.4, 38.5, 36.7, 34.9, 33.0, 32.9, 
31.4, 30.1, 28.8, 27.0, 25.9, 23.7, 21.7, 20.5, 17.4, 16.6, 16.1, 15.2, 14.60, 14.58, 12.0, 11.4, 8.0, 
7.0 ppm; FT-IR (KBr tablet): 3567 (br, m), 3301 (m), 2967 (s), 2939 (s), 2880 (s), 1788 (s), 1702 
(br, s), 1655 (s), 1610 (s), 1588 (m), 1508 (s), 1484 (s), 1461 (s), 1448 (s) cm-1; ESI MS (m/z): 
[M+Na]+ Calcd for C49H73NNaO13 907; Found 907. 
 
4.2.3. General procedure for preparation of novel salinomycin C20-propargylamine 15 
 Method A: To a stirred solution of ketone 14 (1.0 equiv.) in MeOH at room temperature, 
propargylamine (10.0 equiv.) was added, followed by addition of a small portion of acetic acid. 
The resulting yellow solution was stirred for 1 hour at room temperature prior to the addition of 
CeCl3·7H2O (1.0 equiv.), followed by the dropwise addition of a solution of NaBH3CN (2.0 
equiv.) in MeOH over 12 hours using a dropping funnel. Organic solvent was then evaporated to 
dryness under reduced pressure to give a yellow oil. The yellow residue was re-dissolved in 
CH2Cl2, and washed twice with an aqueous solution of H2SO4 (pH = 1.0) and finally with 
distilled water. The organic layer was separated, concentrated under reduced pressure and 
purified on silica gel using the CombiFlash system (50% EtOAc/CHCl3) to give the pure product 
15 (64% yield) as a colorless oil. After 3-times repeated evaporation with n-pentane the oil was 
transformed to a white amorphous solid. 
 Method B: A solution of amine 16 (1.0 equiv.), 1,3-dicyclohexylcarbodiimide (1.2 
equiv.) and propargylamine (2.0 equiv.) in CH2Cl2 was mixed with 1-hydroxybenzotriazole 
hydrate (0.5 equiv.) in THF, and stirred at 0 °C for 1 hour. Then, the reaction mixture was stirred 
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at room temperature for further 24 hours. Afterwards, the organic solvents were evaporated 
under reduced pressure to dryness. The yellow residue was re-suspended in CH2Cl2 and filtered 
to remove the 1,3-dicyclohexylurea by-product. The filtrate was evaporated under reduced 
pressure and purified on silica gel using the CombiFlash system (50% EtOAc/CHCl3) to give the 
pure product 15 (38% yield) as a colorless oil. After 3-times repeated evaporation with n-pentane 
the oil was transformed to white amorphous solid. 
 
4.2.3.1. Propargyl amide of C20-propargylaminosalinomycin 15 
Yield: 230 mg, 64%. Isolated as a white amorphous solid, >95% pure by NMR and a 
single spot by TLC; Rf: 0.41 in 50% EtOAc/n-hexane. Strains green with PMA; 1H NMR (400 
MHz, CD2Cl2) δ 7.27 (t, J = 5.5 Hz, 1H), 6.10 (dd, J = 10.7, 2.2 Hz, 1H), 5.95 (dd, J = 10.7, 1.6 
Hz, 1H), 4.37 (ddd, J = 17.6, 5.9, 2.5 Hz, 1H), 4.18 (ddd, J = 17.6, 5.3, 2.5 Hz, 1H), 4.07 (d, J = 
9.6 Hz, 1H), 3.93–3.85 (m, 1H), 3.80 (dd, J = 13.7, 6.8 Hz, 1H), 3.68 (ddd, J = 20.1, 10.0, 2.3 
Hz, 2H), 3.58 (dd, J = 11.8, 2.2 Hz, 1H), 3.46 (qd, J = 16.8, 2.4 Hz, 2H), 3.19 (t, J = 1.8 Hz, 1H), 
3.00–2.82 (m, 2H), 2.70–2.56 (m, 2H), 2.54–2.47 (m, 1H), 2.24 (ddd, J = 11.5, 8.2, 6.1 Hz, 2H), 
2.14–2.03 (m, 2H), 1.92–0.54 (m, 53H) ppm; 13C NMR (101 MHz, CD2Cl2) δ 212.9, 175.3, 
132.4, 119.9, 106.7, 98.7, 89.0, 82.8, 82.2, 79.5, 77.3, 75.7, 74.6, 71.3, 71.1, 71.0, 69.4, 69.0, 
55.5, 53.8, 48.2, 46.9, 40.8, 38.7, 37.9, 37.6, 36.6, 32.9, 30.9, 30.8, 29.6, 28.9, 28.6, 27.1, 25.9, 
22.43, 22.40, 20.7, 17.6, 17.4, 15.9, 14.8, 14.6, 14.5, 12.0, 11.7, 8.2, 6.6 ppm; FT-IR (KBr 
tablet): 3484 (s), 3434 (br, m), 3312 (s), 2963 (s), 2935 (s), 2877 (s), 1712 (s), 1668 (s), 1524 (s), 
1459 (s), 1419 (m), 1403 (m) cm-1; ESI MS (m/z): [M+H]+ Calcd for C48H77N2O9 826; Found 
826. 
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4.3. X-ray measurements 
X-ray data collection for colorless single crystals of 14 and 15 was performed on a four-
circle KUMA KM-4 diffractometer equipped with a two-dimensional CCD area detector. The 
graphite monochromatized MoK radiation (=0.71973 Å) and the  scan technique (=1o) 
were used for data collection. Data collection and reduction along with absorption correction 
were performed using CrysAlis software package [32]. The structure was solved by direct 
methods using the SHELXT program revealing positions of almost all non-hydrogen atoms. The 
remaining atoms were located from subsequent difference Fourier syntheses. The structure was 
refined using SHELXL-2014 [33] with the anisotropic thermal displacement parameters. The 
hydrogen atoms of the aromatic ring were refined with riding model. Visualization of the 
structures was made with the Diamond 3.0 program [34]. Details of the data collection 
parameters, crystallographic data and final agreement parameters are given in Table S1 
(Supplementary Information). Hydrogen bonding geometry is collected in Table S2 
(Supplementary Information). 
 
4.4. In vitro biological studies 
4.4.1. Cell Culture 
Bloodstream form of T. brucei 427-221a [35] and human myeloid HL-60 cells [36] were 
in cultured in Baltz medium [37] supplemented with 16.7% heat-inactivated bovine serum. All 
cultures were maintained at 37 °C in a humidified atmosphere containing 5% carbon dioxide. 
 
4.4.2. Trypanocidal and cytotoxic assays 
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Toxicity assays were performed as previously described [28,29]. In brief, trypanosomes 
and HL-60 cells were seeded at an initial cell density of 1  104 ml-1 and 5  104 ml-1, 
respectively, in 96-well plates in a final volume of 200 μl of Baltz medium containing various 
concentrations of test compounds (tenfold dilutions from 100 μM to 1 pM) and 0.9% DMSO. 
Wells containing only Baltz medium and 0.9% DMSO served as controls. After 24 h incubation, 
20 μl of a 0.5 mM resazurin solution prepared in PBS and sterile filtered was added. Incubation 
was continued for another 48 h and then the absorbance of the wells was read on a BioTek 
ELx808 microplate reader using a test wavelength of 570 nm and a reference wavelength of 630 
nm. The GI50 value (i.e. the concentration of a compound necessary to reduce the growth rate of 
cells by 50% compared to the control) was determined by linear interpolation according to the 
method described by Huber and Koella [38]. 
 
4.4.3. Swelling experiments 
Changes in cell volume were measured by the light scattering methods as previously 
described [20]. Briefly, bloodstream forms of T. brucei were incubated at a cell density of 5  
107 cells ml-1 in 96-well plates in a final volume of 200 µl Baltz medium containing 100 µM 
ionophore and 0.9% DMSO. Controls contained just 0.9% DMSO. Absorbance of the cultures 
was measured at 490 nm on a BioTEk ELx808 microplate reader every 10 min for an hour. 
 
Supporting Information 
The structures have been deposited with the Cambridge Crystallographic Data Center in 
the CIF format, no. CCDC 1879997 and 1879998 for 14 and 15, respectively. Copies of this 
information can be obtained free of charge from The Director, CCDC, 12 Union Road, 
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Cambridge, CB2 1EZ, UK (fax: +44 1223 336 033); E-mail: deposit@ccdc.cam.ac.uk or www: 
http://www.ccdc.cam.ac.uk. 
Additional figures illustrating the mutual overlap of structures 13‒15 from scXRD 
analysis as well as 1H, 13C and 19F NMR spectra of the newly synthesized compounds are 
available free of charge via Internet at http://xxx. 
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